- Telehealth Visits
- Insurance plan information
Hemali Batra-Sharma, MD
Medical Oncology • Hematology- Telehealth Visits
- Insurance plan information
Hemali Batra-Sharma, MD
Medical Oncology • Hematology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Hemali Batra-Sharma is a medical oncologist who specializes in caring for patients with breast cancer.
In her research, Batra-Sharma aims to evaluate new treatments that could improve outcomes for patients with breast cancer. Her subjects of study have included triple-negative breast cancer (an aggressive type), lobular breast cancer (which begins in the milk-producing glands), and breast cancer that has spread to the brain and leptomeninges (membranes surrounding the brain and spinal cord.
Batra-Sharma earned her medical degree from the Carver College of Medicine at the University of Iowa. At the University of California, San Diego, she completed a residency in internal medicine and a fellowship in hematology-oncology.
Education & training
Board certification
- Hematology, American Board of Internal Medicine/Hematology
- Medical Oncology, American Board of Internal Med/Medical Oncology
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Hematology - Oncology, University of California Medical Center San Diego
Residency
- Internal Medicine, University of California Medical Center San Diego
Degree
- MD, University of Iowa College of Medicine
My expertise
Locations
Clinical Trials query: q=health_gateway_id_ss%3A%28%225014%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%225014%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.